Development and validation of a RP-HPLC method for stability-indicating assay of gemifloxacin mesylate including identification of related substances by LC-ESI-MS/MS, 1H and 13C NMR spectroscopy

Biomedical Chromatography

Volumn 25, Issue 11, 2011, Pages 1222-1229

  Nageswara Rao, R ^a   Naidu, Ch Gangu ^a   Prasad, K Guru ^a   Narasimha, R ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Antibiotics; ESI MS MS; Forced degradation; Gemifloxacin mesylate; Related substances

Indexed keywords

DEGRADATION; EFFLUENTS; PHOTOLYSIS;

DEGRADATION PRODUCTS; ESI-MS-MS; FORCED DEGRADATION; GEMIFLOXACIN MESYLATE; LC-ESI-MS/MS; MESYLATES; NMR-SPECTROSCOPY; RELATED SUBSTANCES; RP-HPLC METHOD; STABILITY-INDICATING ASSAYS;

NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

GEMIFLOXACIN; METHANOL; PEROXIDE; TRIFLUOROACETIC ACID; NAPHTHYRIDINE DERIVATIVE; QUINOLONE DERIVATIVE;

ACCURACY; ACIDITY; ALKALINITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG DETERMINATION; DRUG IMPURITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; PHOTOLYSIS; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; THERMAL ANALYSIS; VALIDATION PROCESS; CHEMISTRY; DRUG CONTAMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; DRUG CONTAMINATION; FLUOROQUINOLONES; LINEAR MODELS; MAGNETIC RESONANCE SPECTROSCOPY; NAPHTHYRIDINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 80053599309     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1594     Document Type: Article

References (14)

1. Devi ML and Chandrasekhar KB. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant. Journal of Pharmaceutical and Biomedical Analysis, 2009; 50: 710-717.
2. Doyle E, Fowles SE, McDonnell DF, McCarthy R and White SA. Rapid determination of gemifloxacin in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Journal of Chromatography. B: Biomedical Sciences and Applications 2000; 746: 191-198.
3. Elbashir AA, Saad B, Ali ASM, Al-Azzam KMM and Aboul-Enein HY. Validated stability indicating assay of gemifloxacin and lomefloxacin in tablet formulations by Capillary Electrophoresis. Journal of Liquid Chromatography and Related Technologies 2008; 31: 1465-1477.
4. Grellet J, Ba B and Saux MC. High-performance liquid chromatographic separation of fluoroquinolone enantiomers: a review. Journal of Biochemical and Biophysical Methods 2002; 54: 221-233.
5. ICH. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Good Manufacturing Practices Guide for Active Pharmaceutical Ingredients, 2000; Q7A.
6. ICH. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Impurities in New Drug Substances, 2002; Q3A (R1).
7. Kim E, Koo YM and Chung DS. Chiral counter-current chromatography of gemifloxacin guided by capillary electrophoresis using (+)-(18-crown-6)-tetracarboxylic acid as a chiral selector. Journal of Chromatography A 2004; 1045: 119-124.
8. Kumar YR, Raju VVNKVP, Kumar RR, Eswaraiah S, Mukkanti K, Suryanarayana MV and Reddy MS. Structural identification and characterization of impurities in moxifloxacin. Journal of Pharmaceutical and Biomedical Analysis, 2004; 34: 1125-1129.
9. Lee W and Hong CY. Direct liquid chromatographic enantiomer separation of new fluoroquinolones including gemifloxacin. Journal of Chromatography A 2000; 879: 113-120.
10. Ranjane PN, Gandhi SV, Kadukar SS and Bothara KG. Stability indicating RP-LC method for the determination of gemifloxacin mesylate. Chromatographia 2010; 71: 1113-1117.
11. Rao RN and Nagaraju V. An overview of the recent trends in development HPLC methods for determination of impurities in drugs. Journal of Pharmaceutical and Biomedical Analysis 2003; 33: 335-377.
12. Rao RN, Raju AN and Narsimha R. Isolation and characterization of process related impurities and degradation products of bicalutamide and development of RP-HPLC method for impurity profile study. Journal of Pharmaceutical and Biomedical Analysis 2008a; 46: 505-519.
13. Rao RN, Talluri MVNK and Shinde DD. Simultaneous separation and determination of coenzyme Q10 and its process related impurities by NARP-HPLC and atmospheric pressure chemical ionization-mass spectrometry (APCI-MS). Journal of Pharmaceutical and Biomedical Analysis 2008b; 47: 230-237.
14. Rote AR and Pingle SP. Reverse phase-HPLC and HPTLC methods for determination of Gemifloxacin mesylate in human plasma. Journal of Chromatography B 2009; 877: 3719-3723.